Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Ibrutinib may be taken alone or in combination with another medication as an initial (first-line) treatment.
Long-term ibrutinib treatment increases T cell numbers and improves T cell function in CLL patients but does not fully restore T cell function.
Long-term follow-up data confirms the sustained benefit of ibrutinib therapy for CLL / SLL, including uMRD, in a small subset of patients.
A combination of ibrutinib plus venetoclax is a very effective first-line treatment for CLL, and 90% of patients are progression-free after five years.
The FDA approved an oral suspension of ibrutinib for adults with chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL).
Patients with relapsed/refractory CLL / SLL treated with zanubrutinib had longer remissions than patients treated with ibrutinib.
Measurable residual disease (MRD)-guided treatment of CLL with ibrutinib plus venetoclax significantly increased time in remission.
Mutations at BTK C481 are the most common mutations seen in pooled trial data of chronic lymphocytic leukemia (CLL) patients on ibrutinib, leading to resistance and progressive disease (PD).
A newly published paper in JAMA Oncology found that among cancer patients with suspected ibrutinib-related cardiotoxic effects, the presence of heart muscle injury and scarring is high, and this is associated with an increased risk of developing future cardiovascular adverse events.
One click to our most popular content.
